Investigational Drug Information for AZD4635
✉ Email this page to a colleague
What is the drug development status for AZD4635?
AZD4635 is an investigational drug.
There have been 7 clinical trials for AZD4635.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 29th 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Parexel, and MedImmune LLC.
There are one hundred and eight US patents protecting this investigational drug and one hundred and forty-nine international patents.
Summary for AZD4635
| US Patents | 108 |
| International Patents | 149 |
| US Patent Applications | 315 |
| WIPO Patent Applications | 149 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 1 (2019-08-29) |
| Vendors | 53 |
Recent Clinical Trials for AZD4635
| Title | Sponsor | Phase |
|---|---|---|
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | Parexel | Phase 2 |
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | AstraZeneca | Phase 2 |
| A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers | Parexel | Phase 1 |
Clinical Trial Summary for AZD4635
Top disease conditions for AZD4635
Top clinical trial sponsors for AZD4635
US Patents for AZD4635
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD4635 | ⤷ Start Trial | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited (Welwyn Garden, GB) | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | Microparticle formulations of adenosine receptor antagonists for treating cancer | PHOSPHOREX, INC. (Hopkinton, MA) | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | Methods for treating cancer using HSP90 inhibitors | A1 Therapeutics, Inc. (Guilford, CT) | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | PD-1/PD-L1 inhibitors | Gilead Sciences Inc | ⤷ Start Trial |
| AZD4635 | ⤷ Start Trial | 1,2,4-triazine-4-amine derivatives | Biofocus DPI Ltd , Nxera Pharma UK Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD4635
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD4635 | Australia | AU2011212430 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | Brazil | BR112012019540 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | Canada | CA2789279 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | China | CN102822150 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | Cyprus | CY1117780 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | Denmark | DK2531492 | 2030-02-05 | ⤷ Start Trial |
| AZD4635 | European Patent Office | EP2531492 | 2030-02-05 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
